Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response
2011

Enhancing Radiosensitivity in Glioblastoma Cells with BO-1051

publication 10 minutes Evidence: moderate

Author Information

Author(s): Chu Pei-Ming, Chiou Shih-Hwa, Su Tsann-Long, Lee Yi-Jang, Chen Li-Hsin, Chen Yi-Wei, Yen Sang-Hue, Chen Ming-Teh, Chen Ming-Hsiung, Shih Yang-Hsin, Tu Pang-Hsien, Ma Hsin-I

Primary Institution: National Defense Medical Center & Taipei Veterans General Hospital

Hypothesis

Can BO-1051 enhance the radiosensitivity of human glioblastoma cells?

Conclusion

BO-1051 effectively enhances glioma cell radiosensitivity both in vitro and in vivo.

Supporting Evidence

  • BO-1051 significantly inhibited growth of glioma cells in a dose-dependent manner.
  • The sensitizer enhancement ratio for radiosensitivity was between 1.24 and 1.50.
  • Combined treatment with BO-1051 and radiation resulted in a greater number of γ-H2AX foci, indicating prolonged DNA damage.
  • In vivo studies showed that BO-1051 enhanced the radiotherapeutic effects on xenograft tumors.

Takeaway

Researchers found that a drug called BO-1051 helps make brain cancer cells more sensitive to radiation treatment, which could help patients get better results from their therapy.

Methodology

The study used clonogenic assays, DNA damage assessment via γ-H2AX foci, and in vivo tumor growth delay assays in mice.

Limitations

The study did not explore the long-term effects of BO-1051 or its potential side effects in humans.

Participant Demographics

The study involved human glioma cell lines and nude mice for in vivo experiments.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1748-717X-6-7

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication